Tumor-specific Antigen is a new Antigen that is expressed on the surface of certain Tumor cells but not on normal cells.Such antigens may be present in tumors of the same tissue type in different individuals.Tumor-specific antigens help the body develop an immune response to cancer cells.They could be used as potential targets for targeted therapy or immunotherapy to help improve the body's immune system to kill more cancer cells.Tumor-specific antigens can also be used in laboratory tests to help identify certain types of cancer.
This report contains market size and forecasts of Tumor-Specific Antigen in Global, including the following market information:
Global Tumor-Specific Antigen Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Tumor-Specific Antigen market was valued at 2204.1 million in 2021 and is projected to reach US$ 3142.3 million by 2028, at a CAGR of 5.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Coding Region Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tumor-Specific Antigen include Agilent Technologies, Creative Diagnostics, Go Therapeutics, Lee Biosolutions, Bio-Rad, Biomrieux, Caris Life Sciences, Roche and Abcam, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor-Specific Antigen companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor-Specific Antigen Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Tumor-Specific Antigen Market Segment Percentages, by Type, 2021 (%)
Coding Region
Non-Coding Region
Global Tumor-Specific Antigen Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Tumor-Specific Antigen Market Segment Percentages, by Application, 2021 (%)
Drug Discovery and Development
Diagnostics
Clinical and Basic Research
Others
Global Tumor-Specific Antigen Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Tumor-Specific Antigen Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor-Specific Antigen revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Tumor-Specific Antigen revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Agilent Technologies
Creative Diagnostics
Go Therapeutics
Lee Biosolutions
Bio-Rad
Biomrieux
Caris Life Sciences
Roche
Abcam
Merck Group
PerkinElmer
OriGene Technologies